Revenue Breakdown
Composition ()
No data
Revenue Streams
Cytek Biosciences Inc (CTKB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Biotechnology, pharmaceutical, distributor and CRO, accounting for 66.0% of total sales, equivalent to $34.50M. Another important revenue stream is Academia and government. Understanding this composition is critical for investors evaluating how CTKB navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Cytek Biosciences Inc maintains a gross margin of 52.92%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -9.00%, while the net margin is -70.93%. These profitability ratios, combined with a Return on Equity (ROE) of -18.05%, provide a clear picture of how effectively CTKB converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CTKB competes directly with industry leaders such as BBNX and VREX. With a market capitalization of $570.76M, it holds a leading position in the sector. When comparing efficiency, CTKB's gross margin of 52.92% stands against BBNX's 58.98% and VREX's 33.30%. Such benchmarking helps identify whether Cytek Biosciences Inc is trading at a premium or discount relative to its financial performance.
